ɪɾ ɪz ɐ sᵻlˈɛktɪv pˈæntˌiːˌɑːɹkˈeɪ ɹᵻsˈɛptɚ tˈaɪɹəsˌaɪn kˈɪneɪs ɪnhˈɪbɪɾɚ tˌiːkˌeɪˈaɪ tˈɑːɹɡɪɾɪŋ dʒˈiːn fjˈuːʒənz ɪn tˌiːˌɑːɹkˈeɪ ˈeɪ, tˌiːˌɑːɹkˈeɪ bˈiː ðɪs dʒˈiːn, ænd tˌiːˌɑːɹkˈeɪ sˈiː ɹᵻspˈɛktɪvli, kˈoʊdᵻd baɪ ˌɛntˌiːˌɑːɹkˈeɪ wˈʌn, ˌɛntˌiːˌɑːɹkˈeɪ tˈuː, ænd ˌɛntˌiːˌɑːɹkˈeɪ θɹˈiː dʒˈiːnz ðæt ɪz kˈɜːɹəntli ɪn fˈeɪz tˈuː klˈɪnɪkəl tˈɛstɪŋ.
It is a selective pan-trk receptor tyrosine kinase inhibitor (TKI) targeting gene fusions in trkA, trkB (this gene), and trkC (respectively, coded by NTRK1, NTRK2, and NTRK3 genes) that is currently in phase 2 clinical testing.